Investment thesisEquityHealthcare
Oscar Health logo

OSCR

Oscar Health

A speculative position on growth plus genuine AI use inside insurance operations.

Portfolio weight

2.89%

As of August 20, 2026

Growth and the technology angle

This is a more speculative healthcare position. The appeal is strong growth combined with significant use of AI inside the insurance operation itself, applied to claims handling, utilization review and administrative cost rather than used as a marketing layer.

For a smaller insurer that matters more than it would for an incumbent, because administrative expense is a larger share of the cost base. It is not sufficient on its own: underwriting still has to price medical cost correctly.

Why the position stays small

Oscar's revenue is concentrated in the ACA marketplace, which makes it directly exposed to subsidy policy and to annual risk-pool composition. A single unfavorable enrolment year, or a change to subsidy structure, moves the economics considerably.

Reported earnings are also early and volatile, swinging on reserve development. Policy sensitivity plus thin, unstable margins is why I hold this small and treat it as speculative.

Reported financials

Financial data through Q2 2026

Premiums earned, net

SEC XBRL

Financial data through Q2 2026 · SEC XBRL: PremiumsEarnedNet. Q4 derived as the fiscal-year total less the other three quarters, since XBRL has no standalone Q4 duration.

Revenue growth (YoY)

SEC XBRL

Financial data through Q2 2026 · Year-over-year change, same quarter prior year, from SEC-reported figures.

Operating margin

SEC XBRL

Financial data through Q2 2026 · Computed from SEC-reported operatingIncome ÷ revenue.

Relative valuation

Valuation updated August 2026

Forward P/E

Not applicable. Earnings are early and volatile; the multiple swings on reserve development.

Direct peers

used in the average

Similar enough that comparing multiples is meaningful.

ALHC

ALHC

Alignment Healthcare

86% similar

fwd P/E pending

same business modelsame revenue modelsame end markets
CLOV

CLOV

Clover Health

86% similar

fwd P/E pending

same business modelsame revenue modelsame end markets
CNC

CNC

Centene

82% similar

fwd P/E pending

same business modelsame revenue modelsame end markets
HUM

HUM

Humana

68% similar

fwd P/E pending

same business modelsame revenue modelsimilar capital intensity
CI

CI

The Cigna Group

68% similar

fwd P/E pending

same business modelsame revenue modelsimilar capital intensity

Strategic competitors

never averaged

Competing for the same customers or budget, but too different financially for their multiple to say much about this holding.

UnitedHealth Group logo

UNH

UnitedHealth Group

66% similar

fwd P/E pending

same business modelsame revenue modelsimilar capital intensity

Excluded from peer average: too diversified for a clean multiple comparison

Selected by weighted similarity across business model, revenue model, products, end markets, customer type, capital intensity, growth, margins and geography. Direct peers score ≥55% and sit within 2 diversification steps; only they feed the peer average.